艾伏尼布片Ivosidenib 250mg

Newly diagnosed acute myeloid leukemia (AML) Relapsed or refractory acute myeloid leukemia (AML) Cholangiocarcinoma

Recommended Dose: 500 mg orally once daily, with or without food, until disease progression or unacceptable toxicity occurs. Dietary Precaution: Avoid high-fat meals. Dose Adjustment for QTc Prolongation: If the QTc interval increases to 480–500 milliseconds, reduce or interrupt ivosidenib.

Special Populations: The administration of this product to pregnant women, pediatric patients and elderly patients shall be in accordance with the physician’s instructions. Lactation: Lactating women should discontinue breastfeeding during treatment. QTc Prolongation: Monitor the QTc interval and adjust the dose as required. Guillain-Barré Syndrome: Monitor patients for new signs and symptoms, including motor and/or sensory findings. Permanently discontinue ivosidenib in patients diagnosed with Guillain-Barré Syndrome.

In Patients with Acute Myeloid Leukemia (AML): The most common adverse reactions include fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, QTc interval prolongation, rash, cough, decreased appetite, myalgia, constipation, and pyrexia. In Patients with Cholangiocarcinoma: The most common adverse reactions include fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash.

60 tablets per bottle.

Store at room temperature (20–25℃). Keep out of the reach of children.